News stories about Aeglea Bio Therapeutics (NASDAQ:AGLE) have trended somewhat positive recently, according to Accern Sentiment. The research group identifies positive and negative media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Aeglea Bio Therapeutics earned a news sentiment score of 0.22 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 44.4036102128865 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Separately, Zacks Investment Research cut shares of Aeglea Bio Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, January 9th.
Aeglea Bio Therapeutics (AGLE) traded up $0.44 during mid-day trading on Tuesday, hitting $5.89. 38,200 shares of the company’s stock were exchanged, compared to its average volume of 81,967. Aeglea Bio Therapeutics has a 12-month low of $2.81 and a 12-month high of $8.14. The stock has a market capitalization of $99.35 and a PE ratio of -3.22.
Aeglea Bio Therapeutics Company Profile
Aeglea BioTherapeutics, Inc is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company’s product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine.
Receive News & Ratings for Aeglea Bio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.